Pulmonary Surfactant Market - Latest Advancement & Future Trends (2024-2032)

Pulmonary Surfactant Market Synopsis:

Pulmonary Surfactant Market Size Was Valued at USD 578.05 Billion in 2023, and is Projected to Reach USD 919.10 Billion by 2032, Growing at a CAGR of 4.9% From 2024-2032.

The Pulmonary Surfactant Market is defined as the global market trend for surfactant products applied to the management of respiratory disorders, particularly respiratory distress syndrome amongst infants and adults with jeopardized lungs. Pulmonary surfactants are specific types of substances which decrease surface tension in the lungs so that the alveoli don’t collapse for the proper exchange of gases to occur. They are essential in management of Respiratory Distress Syndrome (RDS) in preterm neonates, Acute Respiratory Distress Syndrome (ARDS) in adult, and every other situation that affected normal lung function. These surfactants can include products made from animal lungs or can be totally synthetic in nature. It is expanding because of the higher rate of preterm births, a higher number of respiratory diseases and enhanced neonatal care as well as the improved methods for the treatment of respiratory illnesses in grownups.

The market for Pulmonary Surfactant is on a positive growth trajectory, due to the increasing prevalence of Respiratory Distress Syndrome in premature babies, Acute Respiratory Distress Syndrome in adults and other respiratory disorders. Pulmonary surfactants are responsible for reducing the surface tension in the lungs lowering chances of alveolar collapse and facilitating effective gas exchange. These products are used chiefly in NICUs for premature babies and in ICUs for severely ill adult patients with acute respiratory failure caused by trauma, infections, or viral diseases, including COVID-19. Thanks to the improved formulas of surfactants there is a trend toward a growth in the market, the need for new and even safer means for the treatment of neonatal and respiratory diseases in adults.

The market’s growth is also thanks to synthetic and recombinant surfactant development and the increased preference for animal-free products. This market is dominated by North America, due to the developed healthcare industry and high incidences of preterm births. Nonetheless, it is predicted that the growth rate in the Asia-Pacific region will be the highest boosted by increasing access to healthcare services and a higher prevalence of respiratory disorders in newly industrialized nations. This can can also be attributed to the extension of developments in surfactant treatments together with increased preterm birth rate estimates over the forecast timeframe.

Pulmonary Surfactant Market Trend Analysis:

Advancements in Recombinant and Synthetic Surfactants

• The next big development as seen in the current structure of the market is the emergence of new generation recombinant and synthetic surfactants. Recombinant surfactants are created using genetic techniques then the synthesis of surfactants with similar characteristics to the natural human surfactant that is less irritating to human lungs is possible. Compared with trad Bead Surfactant derived of animal, the recombinant one has no risk of transmitting animal-borne diseases and the ethic problems in using animals. In addition, such surfactants can be produced in large quantities for a relatively longer interval leaving least deviation in quality. This trend is also very significant in neonatal care where safe and consistent surfactants required to treat RDS in premature babies is paramount.
• As for synthetic surfactants they are also improving with time and developing better recipes for their production that will effectively reduce the side effects. These surfactant are usually formulated from surfactant lipids and proteins and are more stable than the natural ones. Advances in synthetic surfactant technology have allowed production of new products that are easier to store and are more shelve stable and cheaper to produce making them ideal for mass production. With the increasing market need for better cost effective solutions for neonatal RDS and adult respiratory distress syndromes; recombinant and synthetic surfactants will surely build the foundation to provide enhanced respiratory care treatments to patients worldwide.

Rising Preterm Births and Neonatal Care Demand

• The increase in preterm birth rates across the world offers a major developing for the pulmonary surfactant market. As cited in WHO, over 15 million babies are being born pre-term annually adding to the increasing statistics associated with numerous factors like maternal age, high risk pregnancy, and lifestyle. Viral pneumonia continues to be a big killer of infants born prematurely or earlier than 28 weeks’ pregnancy, due to under developed lungs they can develop Respiratory Distress Syndrome (RDS). Pulmonary surfactants play an important role in reducing the surface tension in lungs and therefore facilitate breathing in these infants as well as minimizing on severe complications arising from lung injury.
• As neonatal care expands concerning the quality and availability across the world and especially in LMICs, so does the need for pulmonary surfactants. NICU are now changing and the chance of premature infants’ survival has been greatly enhanced by the availability of surfactant. Also, with the improved awareness that there is need for early treatment of preterm infants, chemists use surfactant therapy to increase the chances of survival and to minimize long term complications of preterm birth. This growing focus toward neonatal care together with the incidences of preterm birth will fuel the pulmonary surfactant market and help market players to market new products and enhance patient value propositions at the same time.

Pulmonary Surfactant Market Segment Analysis:

Pulmonary Surfactant Market is Segmented on the basis of Type, Application, End User, and Region.

By Type, Natural Surfactants segment is expected to dominate the market during the forecast period

• The market will again be led by Natural Surfactants segment due to their widely tested and proven proficiency along with historic application in various clinical solutions especially in NRDS. Extracted from animal’s lungs usually from cow or pig, natural surfactant consists of phospholipids and proteins that are similar to the human lung surfactant. This makes them very useful in oil-wet surfaces as they readily reduce the tension in the lungs, thereby preventing the alveoli from collapsing, and enhance the exchange of gases in premature infants. Because they have been the treatment of choice in neonatal care for several years, natural surfactants remain popular in hospitals and neonatal intensive care units (NICUs).
• With the growing emphasis on synthetic and recombinant counterparts, natural surfactants are continuously the leading ones in the market since they are safe for use and clinically effective as confirmed in this book. In the same regard, government regulating agencies like the FDA has for years endorsed animal derived surfactants for use in preterm infants, a fact that has given doctors a lot of confidence in it. This body of evidence available for clinical use of natural surfactants in both RDS and Acute Respiratory Distress Syndrome (ARDS) in adults establishes the products continued place in the pulmonary surfactant market. Global synthetic and recombinant surfactants are steadily emerging in the market, but natural surfactants retain the largest share of the market to the forecast period.

By Application, Neonatal Respiratory Distress Syndrome (RDS) segment expected to held the largest share

• At the same time, the system based on the Neonatal Respiratory Distress Syndrome (RDS) segment is likely to dominate the consumption of pulmonary surfactant during the period in question due to the rising incidence of preterm births across the world. RDS is a frequent and severe complication of premature infants who do not have adequate lungs that make surfactant which reduces the surface tension and thus helps to keep the air sacs open. This is because, as prenatal and perinatal mortalities increase with preterm birth, resulting from factors such as maternal age extra conceptions and organizational aspects of neonatal care; there also arises a greater need to treat preterm births using pulmonary surfactants. Among the biosurfactants used, those that have been used for years in NICUs remain one of the best treatments for Neonatal RDS, which ensures the segment’s market leadership.
• Furthermore, developments in the neonatal intensive care, and an increasing number of NICU beds especially in the BRIC countries are other factors which will help to increase the usage of surfactant agents in premature babies. Thanks to the enhancement of healthcare, especially in Asian Pacific and Latin American countries, the number of premature infants with surfactant therapy will grow and, therefore, stimulate market growth. Furthermore the availability of surfactant therapies that has seen excellent improvements in the survival of the neonates has triggered its use in high risk pregnancies. For this reason, the Neonatal Respiratory Distress Syndrome (RDS) segment is expected to retain its largest market share for the period under consideration with rising global concern for preterm infant care and outcome.

Pulmonary Surfactant Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America has been anticipated to lead the pulmonary surfactant market over the forecast period due to the factors such as, advanced healthcare facilities, high incidence of preterm births, as well as realization of neonatal care technologies. Speaking of regions, the largest volume is observed in the United States because of the successfully developed healthcare system, the availability of NICUs, and the high level of healthcare spendings. Therefore, increasing production of pulmonary surfactants for treatment of RDS in preterm infants: natural and synthetic surfactants are common.
• Besides, enhancing neonatal care, acute respiratory diseases such as ARDS, which became more prominent during the COVID-19 outbreak, created the demand for pulmonary surfactant therapies in adults as well. The rising consciousness on the part of parent and clinicians concerning the necessity of early developmental care needed by preterm infants together with the continuously raising incidences of all forms of respiratory diseases among grownups and a continuous increase in overall life expectancy are seen to be other factors that should continue to fuel this market in North America. In addition, further research, well-developed regulation, and the high innovative activity being observed in the North American market determine this region as a leader in the worldwide consumption of pulmonary surfactants during the entire considered time period.

Active Key Players in the Pulmonary Surfactant Market:

• AbbVie Inc. (United States)
• AstraZeneca PLC (United Kingdom)
• Baxter International Inc. (United States)
• Boehringer Ingelheim GmbH (Germany)
• Chiesi Farmaceutici S.p.A. (Italy)
• F. Hoffmann-La Roche AG (Switzerland)
• GlaxoSmithKline PLC (United Kingdom)
• Johnson & Johnson (United States)
• Merck & Co., Inc. (United States)
• Mylan N.V. (Viatris Inc.) (United States)
• Novartis International AG (Switzerland)
• Pulmatrix, Inc. (United States)
• Respira Therapeutics (United States)
• Sanofi S.A. (France)
• Siemens Healthineers (Germany)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Wockhardt Ltd. (India), and Other Active Players